BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17301973)

  • 1. Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug.
    Duek A; Feldberg E; Haran M; Berrebi A
    Am J Hematol; 2007 Jun; 82(6):502-3. PubMed ID: 17301973
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?
    Pitini V; Arrigo C; Altavilla G; Naro C
    Leuk Res; 2007 Jul; 31(7):1027-8. PubMed ID: 17134751
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe pulmonary complications after bortezomib treatment in multiple myeloma.
    Dun X; Yuan Z; Fu W; Zhang C; Hou J
    Hematol Oncol; 2010 Mar; 28(1):49-52. PubMed ID: 19728395
    [No Abstract]   [Full Text] [Related]  

  • 4. Severe epidermal necrolysis after bortezomib treatment for multiple myeloma.
    Fang B; Song Y; Ma J; Zhao RC
    Acta Haematol; 2007; 118(2):65-7. PubMed ID: 17505132
    [No Abstract]   [Full Text] [Related]  

  • 5. Deafness associated with the use of Bortezomib in multiple myeloma.
    Chim CS; Wong LG
    Acta Oncol; 2008; 47(2):323-4. PubMed ID: 17851876
    [No Abstract]   [Full Text] [Related]  

  • 6. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
    Richardson P
    Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
    [No Abstract]   [Full Text] [Related]  

  • 7. Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance.
    Foley PW; Hamilton MS; Leyva F
    J Cardiovasc Med (Hagerstown); 2010 May; 11(5):386-8. PubMed ID: 19584744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
    Muta T; Nakanishi H; Yasunaga M; Senba S; Murakami H; Kan S; Ueda Y; Fujisaki T
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):237-41. PubMed ID: 21368487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudomembranous colitis following bortezomib therapy in a myeloma patient.
    Moon SJ; Min CK; Lee DG; Lee S; Lee JW; Min WS; Kim CC; Kim M; Park G; Kim Y
    Acta Haematol; 2007; 117(4):211-4. PubMed ID: 17237615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperlipidemia in a myeloma patient after bortezomib treatment.
    Gozzetti A; Fabbri A; Defina M; Chitarrelli I; Bocchia M
    Leuk Res; 2010 Sep; 34(9):e250. PubMed ID: 20363499
    [No Abstract]   [Full Text] [Related]  

  • 11. Bortezomib-induced skin eruption.
    Sanchez-Politta S; Favet L; Kerl K; Dietrich PY; Piguet V
    Dermatology; 2008; 216(2):156-8. PubMed ID: 18216478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib-induced severe hepatitis in multiple myeloma: a case report.
    Rosiñol L; Montoto S; Cibeira MT; Bladé J
    Arch Intern Med; 2005 Feb; 165(4):464-5. PubMed ID: 15738379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma.
    Hattori N; Adachi D; Nakashima H; Saito B; Nakamaki T; Tomoyasu S
    Leuk Res; 2009 Apr; 33(4):574-7. PubMed ID: 18838167
    [No Abstract]   [Full Text] [Related]  

  • 14. Bortezomib-induced acute pancreatitis.
    Elouni B; Ben Salem C; Zamy M; Sakhri J; Bouraoui K; Biour M
    JOP; 2010 May; 11(3):275-6. PubMed ID: 20442528
    [No Abstract]   [Full Text] [Related]  

  • 15. Bortezomib-induced Sweet syndrome.
    Knoops L; Jacquemain A; Tennstedt D; Theate I; Ferrant A; Van den Neste E
    Br J Haematol; 2005 Oct; 131(2):142. PubMed ID: 16197442
    [No Abstract]   [Full Text] [Related]  

  • 16. Bortezomib monotherapy in patients with multiple myeloma is associated with reactivation of hepatitis B.
    Goldberg R; Smith E; Bell S; Thompson A; Desmond PV
    Intern Med J; 2013 Jul; 43(7):835-6. PubMed ID: 23841765
    [No Abstract]   [Full Text] [Related]  

  • 17. Adenovirus-associated hemorrhagic cystitis in a patient with plasma cell myeloma treated with bortezomib.
    Yokose N; Hirakawa T; Inokuchi K
    Leuk Res; 2009 Aug; 33(8):e106. PubMed ID: 19285724
    [No Abstract]   [Full Text] [Related]  

  • 18. Cutaneous lymphoid perivascular reaction with atypical CD30+ T cells in a patient with multiple myeloma treated with bortezomib.
    Dehesa L; Bastida J; Limeres-González M; Campos-Adsuar C; Gómez-Duaso J
    Clin Exp Dermatol; 2009 Dec; 34(8):e1031-2. PubMed ID: 20055832
    [No Abstract]   [Full Text] [Related]  

  • 19. Expanding role of bortezomib in multiple myeloma: nursing implications.
    Colson K; Doss DS; Swift R; Tariman J
    Cancer Nurs; 2008; 31(3):239-49. PubMed ID: 18453881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib in multiple myeloma.
    Mateos MV; San Miguel JF
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.